AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02539199
Drug: Misoprostol, modified-release pessary
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Misoprostol pessary (7 ug/h) placed in vaginal fornix until labour is induced or maximum 24 hours
Trial: NCT02539199
Drug: Misoprostol, per-oral tablets
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First day: 50 ug PO in every 4 hours maximum 3 times per day. Second day: 100 ug PO in every 4 hours maximum 3 times per day. Third day: 50 ug vaginally in every 4 hours maximum 3 times per day or until labour is induced.
Trial: NCT03289663
Drug: synergistic combination of insecticides
RxNorm normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: third generation insecticide -treated bednets
Trial: NCT03289663
Drug: Pyrethroids
RxNorm normalized name: Pyrethrins and pyrethroids
DrugBank: Pyrethrum extract (DB11087)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional insecticide
Trial: NCT02047773
Drug: Colomycin
RxNorm normalized name: Colomycin
DrugBank: Colistin (DB00803)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: If there is a clinical deterioration a second antibiotic to augment treatment (Colomycin) will be added for both arms of the study.
Trial: NCT02047773
Drug: Meropenem
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02643563
Drug: Ropivacaine 0.5%
RxNorm normalized name: ROPivacaine 0.5% injectable solution
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.5% is used for low-volume ultrasound-guided interscalene brachial plexus block.
Trial: NCT02643563
Drug: Ropivacaine 1%
RxNorm normalized name: ROPivacaine 1% injectable solution
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ropivicaine 1% is used for low-volume ultrasound-guided interscalene brachial plexus block.
Trial: NCT02844998
Drug: dapoxetine 30 mg on demand
RxNorm normalized name: duloxetine 30 MG
DrugBank: Dapoxetine (DB04884)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapoxetine, a short-acting selective serotonin reuptake inhibitors, has been utilized for the treatment of premature ejaculation in various countries
Trial: NCT02677207
Drug: JNJ-39393406
RxNorm normalized name: JNJ-39393406
DrugBank: JNJ-39393406 (DB11867)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-39393406 100 mg capsules or placebo daily for the first week and 200 mg daily for the rest of the trial
Trial: NCT00776672
Drug: Fosinopril 40mg Tablets
DrugBank: Fosinopril (DB00492)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05149651
Drug: MTA
RxNorm normalized name: HMTA
DrugBank: 5'-S-methyl-5'-thioadenosine (DB02282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ProRoot White MTA® is a bioactive calcium silicate cement which used as pulpotomy agent to treat extensive decayed tooth indicated for pulpotomy.
Trial: NCT00823433
Drug: oral penicillin V
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 grams of oral penicillin V given within 4 hours of delivery.
Trial: NCT00412347
Drug: Insulin Drip Therapy
RxNorm normalized name: INSULIN
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02224443
Drug: dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Experimental: Group A, Continuous pump infusion dexmedetomidine with loading dose at 0.8µg.kg-1 over 10 minutes,followed continuous pump infusion dexmedetomidine at 0.3µg.kg-1.h-1 until 30 minutes before end of operation
Trial: NCT02224443
Drug: dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Group B, Continuous pump infusion dexmedetomidine with loading dose at 0.8µg.kg-1 over 10 minutes,followed continuous pump infusion dexmedetomidine at 0.5µg.kg-1.h-1 until 30 minutes before end of operation
Trial: NCT02224443
Drug: midazolam,fentanyl,etomidate,Cisatracurium besylate
DrugBank: Etomidate (DB00292)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anesthesia induction : 0.05 mg.kg-1 midazolam,4\~5μg.kg-1 fentanyl,1.0\~1.5mg.kg-1etomidate and 0.15 mg.kg-1Cisatracurium besylate
Trial: NCT03007329
Drug: Exenatide
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide will be combined with Dapagliflozin
Trial: NCT03007329
Drug: Exenatide matching Placebo
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide matching Placebo will be combined with Dapagliflozin
Trial: NCT03007329
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dapagliflozin, in both arms
Trial: NCT00500058
Drug: SB-485232
RxNorm normalized name: SB-649868
DrugBank: SB-649868 (DB14822)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB-485232 for injection, 7 mg/vial, will be available as a lyophilized cake. It will be reconstituted with 1.4 mL of water for injection. Each vial of this drug product is a clear, colorless solution containing 5 mg/mL of SB-485232.
Trial: NCT00500058
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab 375 mg/m\^2 will be administered by IV infusion.
Trial: NCT00180973
Drug: Hydroxyurea
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04470804
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus treats in experimental group
Trial: NCT04470804
Drug: Cyclosporine A
RxNorm normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine A uses for active comparator group.
Trial: NCT03709745
Drug: Aflibercept Injection [Eylea]
RxNorm normalized name: aflibercept Injection [Eylea]
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal injection is given as described in the arm description
Trial: NCT03709745
Drug: Ranibizumab Injection [Lucentis]
RxNorm normalized name: ranibizumab Injection [Lucentis]
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal injection is given as described in the arm description
Trial: NCT02302092
Drug: Flomoxef
RxNorm normalized name: flomoxef
DrugBank: Flomoxef (DB11935)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flomoxef intravenous infusion
Trial: NCT02302092
Drug: Cefepime
RxNorm normalized name: Cefepime
DrugBank: Cefepime (DB01413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefepime intravenous infusion
Trial: NCT00362271
Drug: Venlafaxine on Day -4 to day 14, Aripiprazole dosed starting on Day 1: 3 days at 10 mg, 4 days at 1 mg and 7 days at 20 mg.
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, Venlafaxine: 75 mg; Aripiprazole: 10, 15, 20 mg once daily, 14 days.
Trial: NCT00729183
Drug: Odanacatib
RxNorm normalized name: Odanacatib
DrugBank: Odanacatib (DB06670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Odanacatib 50 mg tablets, taken orally once weekly for 24 months.
Trial: NCT00729183
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 tablets (5600 IU) taken orally once weekly for 24 months.
Trial: NCT01083667
Drug: Pyrimethamine
RxNorm normalized name: Pyrimethamine
DrugBank: Pyrimethamine (DB00205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Open Label, dose escalating,
Trial: NCT00360399
Drug: Escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Escitalopram 10 to 20 mg per day for 12 weeks
Trial: NCT00360399
Drug: Duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Duloxetine 30 to 60 mg per day for 12 weeks
Trial: NCT03896295
Drug: M281
RxNorm normalized name: Immunoglobulin g1, anti-(human neonatal fc receptor) (human monoclonal m281 .gamma.-1 chain), disulfide with human monoclonal m281 .lambda.-chain, dimer
DrugBank: Nipocalimab (DB16257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M281 injection administered as intravenous infusion
Trial: NCT04121260
Drug: Daratumumab
RxNorm normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive dose 1 daratumumab with 30,000 U (2000 U/mL) with rHuPH20 SC injection.
Trial: NCT01527682
Drug: Latanoprost, Dorzolamide
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: * Latanoprost 0.005% ophthalmic solution given once a day at nighttime (9.00 PM)~* Dorzolamide 2% ophthalmic solution given three times a day as a monotherapy, two times a day if in combination with latanoprost
Trial: NCT02526615
Drug: Rosiglitazone
RxNorm normalized name: Rosiglitazone
DrugBank: Rosiglitazone (DB00412)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients received either placebo, metformin or rosiglitazone
Trial: NCT02526615
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients received either placebo, metformin or rosiglitazone
Trial: NCT05328778
Drug: Sugammadex
RxNorm normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Each patient received a single dose administration of sugammadex 2mg/kg according to the ideal body weight (IBW) at reappearance of the second twitch of the train-of-four (TOF).
Trial: NCT04931433
Drug: Lignocaine
RxNorm normalized name: Lignocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group A will receive 1.5mg/kg IV lignocaine bolus prior to induction followed by 2mg/kg/hour of lignocaine infusion throughout surgery until wound closure in which the infusion will be halved to 1mg/kg/hour until the end of surgery. The same rate will be infused in the recovery room for another half an hour before participant is discharge.
Trial: NCT00927563
Drug: Tolcapone
RxNorm normalized name: Tolcapone
DrugBank: Tolcapone (DB00323)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pill, 100-300mg/day for 8 weeks
Trial: NCT01857921
Drug: Atorvastatin 40 mg and trimetazidine MR 70 mg/day for 12 months after randomization
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients with mono antiplatelet therapy with aspirin who had had received CABG previously fulfilling all enrollment criteria will be randomly assigned to the type of two groups. Randomization of statin therapy will be done 1:1 to one of two different groups on the web-based program:~1. Test group:~   * Atorvastatin 40 mg and trimetazidine MR 70 mg daily for 12 months after randomization~2. Control group:~   * Pravastatin 20mg daily for 12 months after randomization
Trial: NCT02815657
Drug: Valsartan
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The A sequence was that Valsartan was taken at 160mg qd on Days1-Day12; SP2086 will be administered orally (by mouth) as 200mg on Days 8-Day12.The B sequence was that SP2086 was taken at 200mg qd dose on Days 8-Day12
Trial: NCT01543399
Drug: Tibolone
RxNorm normalized name: TIBOLONE
DrugBank: Tibolone (DB09070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental group will use 2.5mg of tibolone for 30 days
Trial: NCT01357161
Drug: adavosertib
RxNorm normalized name: Adavosertib
DrugBank: Adavosertib (DB11740)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adavosertib capsules, orally, twice a day (BID) for a total of 5 doses starting on Day 1 of each 3-week cycle
Trial: NCT01357161
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: paclitaxel, intravenous (IV) infusion on Day 1 of each 3-week cycle
Trial: NCT01357161
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: carboplatin, IV infusion on Day 1 of each 3-week cycle
Trial: NCT00798460
Drug: adefovir
RxNorm normalized name: Adefovir
DrugBank: Adefovir (DB13868)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: adefovir 10mg
Trial: NCT00798460
Drug: clevudine
RxNorm normalized name: clevudine
DrugBank: Clevudine (DB06683)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: clevudine 30mg
Trial: NCT00798460
Drug: lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: lamivudine 100mg
Trial: NCT01103154
Drug: carvedilol
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6.25mg per day, increase to 6.25mg bid
Trial: NCT01103154
Drug: nadolol + ISMN
RxNorm normalized name: Nadolol
DrugBank: Nadolol (DB01203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nadolol 40-80mg ISMN 10-20mg
Trial: NCT02374814
Drug: Rabies vaccine
RxNorm normalized name: RABIES VACCINE
DrugBank: PIKA rabies vaccine (DB17963)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compare dose schedule and route of administration
Trial: NCT00325676
Drug: Pantoprazole
RxNorm normalized name: Pantoprazole
DrugBank: Pantoprazole (DB00213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02305849
Drug: Peficitinib
RxNorm normalized name: peficitinib
DrugBank: Peficitinib (DB11708)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: oral tablet
Trial: NCT03790800
Drug: urapidil
RxNorm normalized name: urapidil
DrugBank: Urapidil (DB12661)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A standard treatment regime based on intravenous (IV) bolus of 25mg urapidil administered over 1 minute. For those patients initial systolic blood pressure 180, another 25mg urapidil bolus will be given if the systolic blood pressure level persists \>150 after 5 minutes.
Trial: NCT02947867
Drug: aganirsen
RxNorm normalized name: Aganirsen
DrugBank: Aganirsen (DB15369)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aganirsen antisense oligonucleotide against Insulin Receptor Substrate (IRS-1)
Trial: NCT01651780
Drug: Bivalirudin
RxNorm normalized name: Bivalirudin
DrugBank: Bivalirudin (DB00006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bivalirudin is an anticoagulant that binds directly to thrombin in a bivalent and reversible fashion.
Trial: NCT01651780
Drug: Unfractionated Heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin is an anticoagulant.
Trial: NCT04597125
Drug: Radium-223 dichloride (Xofigo, BAY88-8223)
DrugBank: Radium Ra 223 dichloride (DB08913)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive Radium-223 (BAY88-8223) every 4 weeks for a total of 6 administrations via intravenous (IV) injection
Trial: NCT02650401
Drug: Entrectinib
RxNorm normalized name: ENTRECTINIB
DrugBank: Entrectinib (DB11986)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: TRKA/B/C, ROS1, and ALK inhibitor
Trial: NCT04664972
Drug: Docetaxel +Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The experimental group was treated with TP (docetaxel 75mg/m2 day 1 + cisplatin 25 mg/m2 day 1,2,3) neoadjuvant chemotherapy for 6 cycles, 21 days as a cycle.
Trial: NCT01468948
Drug: Octanoic Acid
RxNorm normalized name: Octanoic acid
DrugBank: Caprylic acid (DB04519)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01791049
Drug: TD-1607
RxNorm normalized name: triamcinolone diacetate Injectable Suspension [TDS Forte]
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03799510
Drug: GLA-SE solution
RxNorm normalized name: selenomethionine Se 75
DrugBank: G100 (DB17244)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The lot concentration 10μg/mL for injection of 2.5μg GLA-SE/injection.
Trial: NCT01755663
Drug: Ivabradine and Metoprolol
RxNorm normalized name: metoprolol and ivabradine
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02782052
Drug: Nebulized ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration at V3 or V4 or V5 in a random order:~* Placebo (P; sterile 0.9% sodium chloride solution)~* Or nebulized ipratropium bromide (IB; 0.5mg/2mL) alone~* Or nebulized combination ipratropium bromide with salbutamol (IB+SALB; 0.5mg/2mL + 2.5mg/2.5mL).
Trial: NCT02782052
Drug: Nebulized combination ipratropium bromide with salbutamol
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration at V3 or V4 or V5 in a random order:~* Placebo (P; sterile 0.9% sodium chloride solution)~* Or nebulized ipratropium bromide (IB; 0.5mg/2mL) alone~* Or nebulized combination ipratropium bromide with salbutamol (IB+SALB; 0.5mg/2mL + 2.5mg/2.5mL).
Trial: NCT00467545
Drug: telbivudine
RxNorm normalized name: Telbivudine
DrugBank: Telbivudine (DB01265)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00199251
Drug: RUPATADINE
RxNorm normalized name: Rupatadine
DrugBank: Rupatadine (DB11614)
FDA approved: no
EMA approved: no
PMDA approved: yes
Trial: NCT04019106
Drug: Budesonide in bovine lipid extract surfactant (BLES)
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide in bovine lipid extract surfactant
Trial: NCT02250794
Drug: metformin and sitagliptin
RxNorm normalized name: metformin and sitagliptin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: metformin 750 mg PO twice daily
Trial: NCT02250794
Drug: insulin glargine and insulin lispro
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: insulin glargine given once daily
Trial: NCT02250794
Drug: metformin and sitagliptin
RxNorm normalized name: metformin and sitagliptin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: sitagliptin 100 mg PO once daily
Trial: NCT02250794
Drug: insulin glargine and insulin lispro
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: insulin lispro given three times daily with meals
Trial: NCT00620256
Drug: Timolol gel forming solution, 0.5%
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00620256
Drug: Latanoprost ophthalmic solution
RxNorm normalized name: Latanoprost Ophthalmic Solution
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03783000
Drug: BI 425809
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment T
Trial: NCT00152477
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10mg/mL vial AUC6. Dosed intravenously over 15-30 minutes immediately following paclitaxel, Day 0 of each cycle.~Each cycle to be repeated every three weeks for a maximum of six cycles.
Trial: NCT00152477
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 6mg/mL vial 200 mg/m2 iv over three hours, Day 0. Each cycle to be repeated every 3 weeks for a maximum of 6 cycles.
Trial: NCT02160665
Drug: Tazarotene Cream, 0.05%
DrugBank: Tazarotene (DB00799)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tazarotene Cream, 0.05% (G \& W Laboratories, Inc.)
Trial: NCT00822627
Drug: Influenza Vaccination
RxNorm normalized name: Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine Injection [PedvaxHIB]
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mL Sanofi-Pasteur intramuscular influenza vaccination
Trial: NCT00022204
Drug: pentoxifylline
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04838054
Drug: Stabilized chlorine dioxide oral rinse
DrugBank: Chlorine (DB11109)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received stabilized chlorine dioxide rinse associated with periodontal basic therapy.
Trial: NCT04150146
Drug: Rebamipide SR 150mg after high-fat meal
RxNorm normalized name: bone meal
DrugBank: Rebamipide (DB11656)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Test Drug
Trial: NCT04150146
Drug: Rebamipide SR 150mg under fasting condition
RxNorm normalized name: selenium sulfide
DrugBank: Rebamipide (DB11656)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Reference Drug
Trial: NCT03926741
Drug: GSNO
RxNorm normalized name: S-Nitrosoglutathione
DrugBank: S-Nitrosoglutathione (DB17877)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patient will use a nebulizer to inhale (breathe in) a solution of GSNO followed by repeated measurements of airway function (breathing tests)
Trial: NCT00439543
Drug: Iloprost inhalation
RxNorm normalized name: Iloprost Inhalation Solution
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00964041
Drug: D-cycloserine
RxNorm normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg by mouth weekly, one hour before assessments, for eight weeks.
Trial: NCT00060801
Drug: BIIL 283 BS (Amelubent)
RxNorm normalized name: BS-001
DrugBank: BS-001 (DB17415)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01126268
Drug: Retapamulin (Altabax)
RxNorm normalized name: Retapamulin
DrugBank: Retapamulin (DB01256)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Retapamulin ointment, applied topically twice daily for five days
Trial: NCT00167609
Drug: dehydroepiandrosterone 100 and 400 mg
RxNorm normalized name: ivacaftor
DrugBank: Ivacaftor (DB08820)
FDA approved: yes
EMA approved: yes
PMDA approved: no